JP7261158B2 - 抗体構築物 - Google Patents

抗体構築物 Download PDF

Info

Publication number
JP7261158B2
JP7261158B2 JP2019520869A JP2019520869A JP7261158B2 JP 7261158 B2 JP7261158 B2 JP 7261158B2 JP 2019520869 A JP2019520869 A JP 2019520869A JP 2019520869 A JP2019520869 A JP 2019520869A JP 7261158 B2 JP7261158 B2 JP 7261158B2
Authority
JP
Japan
Prior art keywords
domain
amino acid
acid sequence
sequence
domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019520869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534277A5 (enExample
JP2019534277A (ja
Inventor
ルーカス ベイリー，
ブライアン グレーザー，
チューフェイ リー，
ローランド グリーン，
Original Assignee
インベンラ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インベンラ， インコーポレイテッド filed Critical インベンラ， インコーポレイテッド
Publication of JP2019534277A publication Critical patent/JP2019534277A/ja
Publication of JP2019534277A5 publication Critical patent/JP2019534277A5/ja
Priority to JP2022162426A priority Critical patent/JP7591015B2/ja
Application granted granted Critical
Publication of JP7261158B2 publication Critical patent/JP7261158B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2019520869A 2016-10-19 2017-10-18 抗体構築物 Active JP7261158B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022162426A JP7591015B2 (ja) 2016-10-19 2022-10-07 抗体構築物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662410054P 2016-10-19 2016-10-19
US62/410,054 2016-10-19
US201762549894P 2017-08-24 2017-08-24
US62/549,894 2017-08-24
US201762555498P 2017-09-07 2017-09-07
US62/555,498 2017-09-07
PCT/US2017/057268 WO2018075692A2 (en) 2016-10-19 2017-10-18 Antibody constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022162426A Division JP7591015B2 (ja) 2016-10-19 2022-10-07 抗体構築物

Publications (3)

Publication Number Publication Date
JP2019534277A JP2019534277A (ja) 2019-11-28
JP2019534277A5 JP2019534277A5 (enExample) 2020-11-26
JP7261158B2 true JP7261158B2 (ja) 2023-04-19

Family

ID=60452719

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019520869A Active JP7261158B2 (ja) 2016-10-19 2017-10-18 抗体構築物
JP2022162426A Active JP7591015B2 (ja) 2016-10-19 2022-10-07 抗体構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022162426A Active JP7591015B2 (ja) 2016-10-19 2022-10-07 抗体構築物

Country Status (16)

Country Link
US (3) US20180118811A1 (enExample)
EP (2) EP3529269B1 (enExample)
JP (2) JP7261158B2 (enExample)
KR (3) KR20240000650A (enExample)
CN (3) CN110177805B (enExample)
AU (1) AU2017345454B2 (enExample)
CA (1) CA3041254A1 (enExample)
DK (1) DK3529269T3 (enExample)
ES (1) ES3063689T3 (enExample)
FI (1) FI3529269T3 (enExample)
IL (2) IL326918A (enExample)
LT (1) LT3529269T (enExample)
MX (1) MX421186B (enExample)
PL (1) PL3529269T3 (enExample)
PT (1) PT3529269T (enExample)
WO (1) WO2018075692A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6696982B2 (ja) 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
DK3529269T3 (da) * 2016-10-19 2026-02-23 Invenra Inc Antistof-konstruktioner
WO2019183406A1 (en) * 2018-03-21 2019-09-26 Invenra Inc. Multispecific antibody purification with ch1 resin
CA3094318A1 (en) 2018-03-30 2019-10-03 Merus N.V. Multivalent antibody
WO2019204522A1 (en) * 2018-04-17 2019-10-24 Invenra Inc. Binding molecules
KR102999339B1 (ko) 2018-04-18 2026-07-31 엑셀리시스, 인코포레이티드 항-ror 항체 구조체
US20210380700A1 (en) * 2018-07-06 2021-12-09 Abmax Biopharmaceuticals De-adcc/cdc functions of antibodies and their applications
EP3830129A4 (en) * 2018-07-30 2022-05-04 Invenra, Inc. MULTISPECIFIC TREG BINDING MOLECULES
EP3864051A4 (en) * 2018-10-10 2022-11-23 Zymeworks Inc. ANTIBODY CONSTRUCTS THAT BIND 4-1BB AND TUMOR-ASSOCIATED ANTIGENS AND THEIR USES
WO2020136566A1 (en) 2018-12-24 2020-07-02 Sanofi Multispecific binding proteins with mutant fab domains
CA3171363A1 (en) * 2019-12-20 2021-06-24 Kisoji Biotechnology Inc. Polypeptides, protein complexes and method for making same
MX2022010176A (es) * 2020-02-20 2023-01-16 Win Therapeutics Inc Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso.
MX2023006899A (es) * 2020-12-10 2023-09-04 Invenra Inc Mutaciones ortogonales para heterodimerización.
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
TW202506726A (zh) * 2023-04-07 2025-02-16 美商麥迪紐有限責任公司 雙特異性工程化抗體
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015515275A (ja) 2012-04-20 2015-05-28 メルス・ベー・フェー Ｉｇ様分子の生産方法および生産手段
JP2015527869A (ja) 2011-08-26 2015-09-24 メリマック ファーマシューティカルズ インコーポレーティッド タンデムＦｃ二重特異性抗体
US20150315296A1 (en) 2014-04-02 2015-11-05 Hoffmann-La Roche Inc. Multispecific antibodies
WO2016087650A1 (en) 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905551D0 (en) * 1989-03-10 1989-04-19 Unilever Plc Detergent compositions
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
KR20080080482A (ko) 2005-09-07 2008-09-04 메디뮨 엘엘씨 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
BRPI0820229A2 (pt) 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
AR074584A1 (es) 2008-12-10 2011-01-26 Mersana Therapeutics Inc Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables
JP2012528240A (ja) 2009-05-28 2012-11-12 メルサナ セラピューティックス， インコーポレイテッド 可変速度放出リンカーを含むポリアル−薬物コンジュゲート
JP5784592B2 (ja) 2009-06-03 2015-09-24 イミュノジェン・インコーポレーテッド 抱合方法
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
TWI603739B (zh) 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8945865B2 (en) 2011-03-10 2015-02-03 Eisai R&D Management Co., Ltd. Method for screening for compound capable of enhancing or inhibiting OATP1B1 transport activity, and method for determining expression level of OATP1B1
EP2717916B1 (en) 2011-06-10 2017-03-08 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
CN104822656B (zh) 2012-05-15 2018-05-01 西雅图基因公司 自稳定接头偶联物
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
US20150239970A1 (en) 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
WO2014093394A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
WO2014160360A1 (en) 2013-03-14 2014-10-02 Mersana Therapeutics Inc. Tubulysin compounds and conjugates thereof
WO2015054659A1 (en) 2013-10-11 2015-04-16 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
CN105813653B (zh) 2013-12-19 2020-06-26 西雅图基因公司 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
EP3107557B1 (en) 2014-02-17 2021-06-09 Seagen Inc. Hydrophilic antibody-drug conjugates
CA2942150A1 (en) 2014-04-07 2015-10-15 Seattle Genetics, Inc. Stable formulations for anti-cd19 antibodies and antibody-drug conjugates
US9808528B2 (en) 2014-06-18 2017-11-07 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates and methods of using same
TWI551060B (zh) * 2014-09-24 2016-09-21 衡宇科技股份有限公司 Ｂｃｈ解碼方法及其解碼器
WO2016180941A1 (en) 2015-05-13 2016-11-17 Sanofi Liquid compositions for anti-cd19 antibody-drug conjugates
EP3778602B1 (en) 2015-07-21 2023-07-12 ImmunoGen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
GB2544086B (en) 2015-11-05 2021-04-28 Povey David Drip catcher for a stemmed drinking vessel
TW201731532A (zh) 2016-02-05 2017-09-16 伊繆諾金公司 用於製備細胞結合劑-細胞毒性劑結合物之有效方法
BR112018068461A2 (pt) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
EP3433278A4 (en) 2016-03-25 2019-11-06 Seattle Genetics, Inc. METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
EP3241531A1 (en) * 2016-05-04 2017-11-08 noonee AG Leg unit for a wearable sitting posture assisting device
DK3529269T3 (da) * 2016-10-19 2026-02-23 Invenra Inc Antistof-konstruktioner
CN112384243A (zh) * 2018-04-17 2021-02-19 英温拉公司 三价三特异性抗体构建体
WO2019204522A1 (en) * 2018-04-17 2019-10-24 Invenra Inc. Binding molecules
KR102999339B1 (ko) * 2018-04-18 2026-07-31 엑셀리시스, 인코포레이티드 항-ror 항체 구조체
EP3830129A4 (en) * 2018-07-30 2022-05-04 Invenra, Inc. MULTISPECIFIC TREG BINDING MOLECULES
WO2021145946A1 (en) * 2020-01-13 2021-07-22 Invenra Inc. Multispecific treg binding molecules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527869A (ja) 2011-08-26 2015-09-24 メリマック ファーマシューティカルズ インコーポレーティッド タンデムＦｃ二重特異性抗体
JP2015515275A (ja) 2012-04-20 2015-05-28 メルス・ベー・フェー Ｉｇ様分子の生産方法および生産手段
US20150315296A1 (en) 2014-04-02 2015-11-05 Hoffmann-La Roche Inc. Multispecific antibodies
WO2016087650A1 (en) 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody

Also Published As

Publication number Publication date
CN110177805A (zh) 2019-08-27
EP3529269B1 (en) 2025-11-26
MX2019004690A (es) 2019-09-27
FI3529269T3 (fi) 2026-02-24
KR20240000650A (ko) 2024-01-02
AU2017345454A1 (en) 2019-05-30
CA3041254A1 (en) 2018-04-26
JP2022176374A (ja) 2022-11-25
PL3529269T3 (pl) 2026-06-22
ES3063689T3 (en) 2026-04-20
KR102617264B1 (ko) 2023-12-29
EP3529269A2 (en) 2019-08-28
MX421186B (es) 2025-02-10
US20240043502A1 (en) 2024-02-08
JP7591015B2 (ja) 2024-11-27
JP2019534277A (ja) 2019-11-28
US20180118811A1 (en) 2018-05-03
IL266143B2 (en) 2026-08-01
CN118359705A (zh) 2024-07-19
PT3529269T (pt) 2026-03-03
LT3529269T (lt) 2026-03-25
KR20250044934A (ko) 2025-04-01
IL266143B1 (en) 2026-04-01
DK3529269T3 (da) 2026-02-23
WO2018075692A3 (en) 2019-04-04
AU2017345454B2 (en) 2024-10-31
CN118359704A (zh) 2024-07-19
WO2018075692A2 (en) 2018-04-26
KR20190092380A (ko) 2019-08-07
CN110177805B (zh) 2024-04-02
IL266143A (en) 2019-06-30
NZ752832A (en) 2025-06-27
EP4729535A3 (en) 2026-07-15
US20260184765A1 (en) 2026-07-02
EP4729535A2 (en) 2026-04-22
IL326918A (en) 2026-05-01

Similar Documents

Publication Publication Date Title
JP7591015B2 (ja) 抗体構築物
US20240392002A1 (en) Anti-ror antibody constructs
US20250026861A1 (en) Trivalent trispecific antibody constructs
US20210163594A1 (en) Binding molecules
US20220213225A1 (en) Multispecific treg binding molecules
US20220153844A1 (en) Multispecific treg binding molecules
WO2019183406A1 (en) Multispecific antibody purification with ch1 resin
EA048615B1 (ru) Конструкции антител к ror

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201019

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221007

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221019

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230117

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230316

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230407

R150 Certificate of patent or registration of utility model

Ref document number: 7261158

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250